Your browser doesn't support javascript.
loading
HER2 status in breast cancer--an example of pharmacogenetic testing.
Kroese, Mark; Zimmern, Ron L; Pinder, Sarah E.
Afiliação
  • Kroese M; Consultant in Public Health Medicine, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, UK. mark.kroese@srl.cam.ac.uk
J R Soc Med ; 100(7): 326-9, 2007 Jul.
Article em En | MEDLINE | ID: mdl-17606754
The development of new drugs and associated pharmacogenetic tests will provide an increasing number of challenges to health care systems. In particular, how to evaluate their benefits, prioritize for commissioning purposes and implement a service to provide them in a timely manner. This paper presents an overview of HER2 testing for trastuzumab (Herceptin) treatment in breast cancer cases. Immunohistochemistry and fluorescence in situ hybridization laboratory techniques are described and their HER2 testing performances are compared. Future options for the national provision of HER2 testing by the National Health Service in the UK are also discussed.
Assuntos

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Genes erbB-2 / Anticorpos Monoclonais / Antineoplásicos Tipo de estudo: Guideline / Prognostic_studies Limite: Female / Humans Idioma: En Revista: J R Soc Med Ano de publicação: 2007 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Genes erbB-2 / Anticorpos Monoclonais / Antineoplásicos Tipo de estudo: Guideline / Prognostic_studies Limite: Female / Humans Idioma: En Revista: J R Soc Med Ano de publicação: 2007 Tipo de documento: Article